Paper34278191
Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.
Li Z and 11 others. Res Pract Thromb Haemost, 2021. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Papers, record 34278191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34278191
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31447396 | Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. | Transfus Apher Sci | 2019 | https://conductscience.org/library/papers/31447396 | PubMed |
| 2 | 31033112 | The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. | Haemophilia | 2019 | https://conductscience.org/library/papers/31033112 | PubMed |
| 3 | 10529689 | Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. | Vox Sang | 1999 | https://conductscience.org/library/papers/10529689 | PubMed |
| 4 | 22101900 | The principal results of the International Immune Tolerance Study: a randomized dose comparison. | Blood | 2012 | https://conductscience.org/library/papers/22101900 | PubMed |
| 5 | 17593277 | International workshop on immune tolerance induction: consensus recommendations. | Haemophilia | 2007 | https://conductscience.org/library/papers/17593277 | PubMed |
| 6 | 28574205 | First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties. | Haemophilia | 2017 | https://conductscience.org/library/papers/28574205 | PubMed |
| 7 | 31624794 | Low-dose immune tolerance induction for children with hemophilia A with poor-risk high-titer inhibitors: A pilot study in China. | Res Pract Thromb Haemost | 2019 | https://conductscience.org/library/papers/31624794 | PubMed |
| 8 | 23278996 | Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution? | Haemophilia | 2013 | https://conductscience.org/library/papers/23278996 | PubMed |
| 9 | 23510123 | Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study. | Haemophilia | 2013 | https://conductscience.org/library/papers/23510123 | PubMed |
| 10 | 23157203 | Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. | Br J Haematol | 2013 | https://conductscience.org/library/papers/23157203 | PubMed |
| 11 | 20536988 | Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. | Haemophilia | 2010 | https://conductscience.org/library/papers/20536988 | PubMed |
| 12 | 26632988 | Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors. | Thromb Haemost | 2016 | https://conductscience.org/library/papers/26632988 | PubMed |
| 13 | 16409170 | Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. | Haemophilia | 2006 | https://conductscience.org/library/papers/16409170 | PubMed |
| 14 | 28641362 | Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis. | Haemophilia | 2017 | https://conductscience.org/library/papers/28641362 | PubMed |
| 15 | 28920105 | The impact of von Willebrand factor on factor VIII memory immune responses. | Blood Adv | 2017 | https://conductscience.org/library/papers/28920105 | PubMed |
| 16 | 31343592 | Low-dose Immune Tolerance Induction in Hemophilia: A Single-Center Experience. | J Pediatr Hematol Oncol | 2019 | https://conductscience.org/library/papers/31343592 | PubMed |
| 17 | 20573153 | Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. | Br J Haematol | 2010 | https://conductscience.org/library/papers/20573153 | PubMed |
| 18 | 32744769 | WFH Guidelines for the Management of Hemophilia, 3rd edition. | Haemophilia | 2020 | https://conductscience.org/library/papers/32744769 | PubMed |
| 19 | 11187870 | The German Registry of immune tolerance treatment in hemophilia--1999 update. | Haematologica | 2000 | https://conductscience.org/library/papers/11187870 | PubMed |
| 20 | 18081830 | Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors. | Haemophilia | 2008 | https://conductscience.org/library/papers/18081830 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42148133 | Outcomes of low-dose immune tolerance induction with single-dose rituximab in severe hemophilia A: a single-center retrospective experience. | Front Immunol | 2026 | https://conductscience.org/library/papers/42148133 | PubMed |
| 42088902 | Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42088902 | PubMed |
| 39810987 | Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial. | Res Pract Thromb Haemost | 2025 | https://conductscience.org/library/papers/39810987 | PubMed |
| 39698264 | Advances in Development of Drug Treatment for Hemophilia with Inhibitors. | ACS Pharmacol Transl Sci | 2024 | https://conductscience.org/library/papers/39698264 | PubMed |
| 38910855 | Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL. | Pediatr Investig | 2024 | https://conductscience.org/library/papers/38910855 | PubMed |
| 38185516 | [Chinese guidelines on the diagnosis and management of hemophilia with inhibitors (2023)]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | https://conductscience.org/library/papers/38185516 | PubMed |
| 36313984 | Low-dose immune tolerance induction in children with severe hemophilia A with high-titer inhibitors: Type of factor 8 mutation and outcomes. | Res Pract Thromb Haemost | 2022 | https://conductscience.org/library/papers/36313984 | PubMed |
| 34278191 | Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. | Res Pract Thromb Haemost | 2021 | https://conductscience.org/library/papers/34278191 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| F8 | 2157 | PubTator's text mining | https://conductscience.org/library/genes/2157 | NCBI Gene |
| VWF | 7450 | PubTator's text mining | https://conductscience.org/library/genes/7450 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34278191
GET https://conductscience.org/api/papers/v1/34278191/references?page=2